Építés alatt – nem éles oldal
Belépés
Fut, nem toborozFázis nélkül

Clinical and Molecular Correlates of Response to First Line Treatment in Lichen Planus

A legfontosabb adatok

Ki végzi
University of Aberdeen
Hol
Egyesült Királyság2 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Résztvevők
110 fő, tervezett
Kezdés
2022. febr. 7.
Befejezés
2026. szept. 30.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A vizsgált kezelések
  • No interventions were administered to the patients as a part of this study.
A regiszteradat frissítve
2026. május 22.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 7 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients aged more than 18 years, with confirmed histopathological diagnosis of lichen planus and undergoing topical steroid therapy
  • Participants who have the capacity to consent
  • Participants who show a willingness to attend an initial appointment and a follow-up post-treatment appointment

Ki nem vehet részt

  • Patients on systemic steroids and other immunosuppressive agents for the treatment of lichen planus
  • Cases of graft versus host disease or those suffering from other systemic inflammatory conditions mimicking lichen planus (e.g. connective tissue disease)
  • Pregnant and lactating participants
  • Inability to consent

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Lichen planus is a common inflammatory (swelling and pain of tissue) disease in the general population that affects mostly the mouth although skin and genital areas can also be affected. It can cause considerable discomfort during activities such as eating, talking and tooth brushing and may impair sexual function with an overall deleterious impact on quality of life. There is also increased evidence of cancer in a subtype of lichen planus. Therefore, treatment is essential in these patients to control the symptoms and improve the quality of life.

A teljes eredeti leírásKevesebb

Locally applied steroids are the first line medicines used in the treatment of patients with lichen planus. This medicine can only control the symptoms, but cannot cure the disease. In addition, this treatment cannot be effective in all patients with lichen planus. This may be attributed to differences in host factors, mouth bacteria and individual host responses to bacteria. The exact cause of this disease is also unknown. New studies have shown changes in the balance of mouth bacteria and host responses to bacteria in patients with lichen planus. So the main purpose of our study is to identify clinical(age, gender, related medical conditions, oral health and the presence of deleterious habits like smoking and alcohol consumption), molecular(analysis of oral microbes and immune markers) and histological factors (change within tissue) associated with poor response in lichen planus patients undergoing treatment with locally applied steroid medicines. Overall, knowledge of these factors associated with disease progression is sparse, which limits progress in the realm of development of novel and personalised treatment strategies. In this study, we explore the individual and combined role of different markers in lichen planus for improving diagnosis, predicting disease progression and treatment effectiveness.

A vizsgálat 2 csoportja

  • Oral lichen planus

    No interventions were administered to this group of patients as a part of the study.

    Kezelés: No interventions were administered to the patients as a part of this study.

  • Oro-vulvovaginal lichen planus

    No interventions were administered to this group of patients as a part of the study.

    Kezelés: No interventions were administered to the patients as a part of this study.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
A regiszteradat frissítve
2026. május 22.